The global intravenous immunoglobulin market size was valued at USD 14.81 billion in 2025 and is projected to grow from USD 15.89 billion in 2026 to USD 27.92 billion by 2034, registering a CAGR of 7.3% during the forecast period from 2026 to 2034. North America dominated the intravenous immunoglobulin market with a market share of 43.25% in 2025.
The antibodies produced by the immune system naturally to help fight disease and infection are known as immunoglobulins. IVIG, also known as intravenous immunoglobulin, is a treatment that combines immunoglobulins donated by various individuals to treat a variety of conditions. It is administered intravenously or through a drip. Plasma is used to create IVIG and other immunoglobulins. IVIG is used to lessen the effects of some inflammatory immune-system-related diseases, also referred to as autoimmune diseases. Additionally, it is used to raise immunoglobulin levels that are low or that have fallen because of taking other medications, like rituximab.
Download a Free Sample To learn more about this report,
Growing Demand for High-Concentration IVIG Therapies for Immune and Neurological Disorders
The intravenous immunoglobulin market is witnessing significant growth as healthcare providers increasingly use immunoglobulin therapies for primary immunodeficiencies, autoimmune diseases, and neurological disorders. Growing diagnosis of immune-mediated conditions and expanding treatment access are increasing demand for high-concentration IVIG formulations that enable efficient administration and reliable therapeutic delivery. Plasma-derived therapy manufacturers are investing in collection networks, fractionation capacity, and advanced purification technologies to strengthen immunoglobulin supply and product availability. Continued clinical research into additional therapeutic indications is also broadening the potential application of IVIG products. These developments are improving access to plasma-derived treatments and contributing to overall intravenous immunoglobulin market growth.
Rising Prevalence of Immunodeficiency and Autoimmune Disorders
The intravenous immunoglobulin market is witnessing steady growth due to increasing diagnosis and treatment of primary immunodeficiency diseases, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, and other immune-mediated disorders. IVIG provides concentrated immunoglobulin G antibodies derived from human plasma and is widely used for immune replacement and immunomodulatory therapy. Improved disease awareness and diagnostic capabilities are helping identify patients who require long-term immunoglobulin treatment. Expanding healthcare access and greater recognition of neurological and autoimmune conditions are also increasing utilization. Growing demand is encouraging plasma collection organizations and manufacturers to strengthen production capabilities and improve the availability of plasma-derived therapies.
In April 2025, Takeda continued expanding plasma collection and manufacturing capabilities to support increasing global demand for plasma-derived therapies, including immunoglobulin products.
High Treatment Costs and Dependence on Human Plasma Supply
The intravenous immunoglobulin market faces restraints because manufacturing depends on large volumes of donated human plasma and involves complex collection, purification, testing, and viral safety procedures. Limited plasma availability can constrain production and contribute to periodic supply pressures when demand increases rapidly. IVIG therapy can also involve substantial treatment costs, particularly for patients requiring repeated high-dose infusions over extended periods. Plasma collection and manufacturing facilities must comply with strict regulatory and quality standards, adding further operational costs. Reimbursement limitations and uneven availability of plasma-derived products can restrict patient access, particularly across lower-income healthcare systems and regions with limited plasma collection infrastructure.
In June 2025, plasma-derived therapy manufacturers continued expanding collection networks and production capacity as growing global immunoglobulin consumption increased pressure on reliable supplies of high-quality source plasma.
Expansion of Plasma Collection and Development of Next-Generation Immunoglobulin Therapies
The intravenous immunoglobulin market offers significant opportunities through expansion of plasma collection networks, improvements in fractionation technologies, and development of higher-yield manufacturing processes. Increasing diagnosis of immune-mediated neurological diseases and primary immunodeficiencies provides manufacturers with opportunities to expand access across emerging healthcare markets. Improvements in purification and formulation can potentially increase manufacturing efficiency and treatment convenience while maintaining product safety. Companies are also evaluating immunoglobulin therapies across additional neurological and autoimmune indications, which could broaden their clinical applications. Investment in new plasma centers and manufacturing facilities can further strengthen supply chains and help address increasing demand for immunoglobulin therapies.
In July 2025, Grifols continued expanding its plasma and biopharma infrastructure to strengthen production capacity for immunoglobulins and other plasma-derived medicines amid growing global demand.
Maintaining Product Safety and Ensuring Stable Plasma-Derived Medicine Supply
The intravenous immunoglobulin market faces challenges in maintaining consistent product availability while meeting rigorous safety and quality requirements. IVIG manufacturing combines plasma collected from numerous donors, requiring extensive donor screening, pathogen testing, purification, viral inactivation, and quality-control procedures. Changes in plasma donation volumes can affect raw-material availability, while expanding manufacturing capacity requires significant investment and lengthy regulatory qualification. Manufacturers must also manage transportation and storage requirements while maintaining reliable distribution to hospitals and infusion centers. Balancing rapidly growing clinical demand with plasma availability, manufacturing capacity, and strict safety standards remains a major challenge for the industry.
In October 2025, CSL continued investing in plasma collection and fractionation capabilities to strengthen the supply of immunoglobulins and other plasma-derived therapies as worldwide demand remained elevated.
Myasthenia Gravis is Projected to Register the Fastest Growth at a CAGR of 8.35%
The myasthenia gravis segment is projected to register the fastest growth in the intravenous immunoglobulin market at a CAGR of 8.35% during the forecast period, driven by increasing utilization of IVIG for managing severe symptoms and acute exacerbations of the autoimmune neuromuscular disorder. Intravenous immunoglobulin helps modulate abnormal immune responses and can provide relatively rapid improvement in muscle weakness among selected patients. Increasing diagnosis of autoimmune neurological disorders, expanding access to immunomodulatory therapies, and growing awareness of effective treatment approaches continue to support demand for IVIG in myasthenia gravis management.
Request Customizationto receive a tailored report.
Hospital Pharmacy Dominated the Market with 68.4% Share in 2025
The hospital pharmacy segment accounted for the largest share of the global intravenous immunoglobulin market at 68.4% in 2025, supported by the extensive administration of IVIG therapies in hospitals under professional medical supervision. Intravenous immunoglobulin is commonly used for treating immune deficiencies, autoimmune diseases, and neurological disorders that may require controlled dosing and patient monitoring. Hospitals also manage patients with severe and complex conditions requiring immediate access to immunoglobulin therapies. Growing treatment volumes, expanding hospital infrastructure, and increasing availability of specialized infusion services continue to reinforce the segment's dominant market position.
Speak to an Analystto discuss market opportunities.
North America dominated the intravenous immunoglobulin market with the largest 43.25% market share in 2025, representing a market value of USD 6.41 billion. The region is projected to grow at a CAGR of 7.18% during the forecast period. Its leadership is supported by advanced healthcare infrastructure, widespread availability of immunoglobulin therapies, established plasma collection networks, and strong demand for treatments addressing immune deficiencies and autoimmune and neurological disorders. Hospitals and specialty clinics extensively utilize intravenous immunoglobulin for patients requiring antibody replacement or immunomodulatory therapy. Growing diagnosis of immune-related conditions and continued expansion of specialty treatment services are supporting consumption. Continued healthcare investment strengthens North America's position in the global intravenous immunoglobulin market.
The United States is an important contributor to the intravenous immunoglobulin market due to its advanced healthcare infrastructure, extensive plasma collection ecosystem, large network of specialty treatment centers, and strong presence of plasma-derived therapy manufacturers. Intravenous immunoglobulin is used across immunology, neurology, hematology, and other medical specialties for patients requiring antibody replacement or immunomodulatory treatment. Improving diagnosis of primary immunodeficiency disorders and growing clinical management of autoimmune and neurological diseases support therapy utilization. Hospitals, specialty clinics, and infusion centers provide established channels for treatment administration. Continued development of plasma collection, fractionation, and specialty therapeutic capabilities supports growth of the country's intravenous immunoglobulin market.
Canada contributes to the intravenous immunoglobulin market through its established healthcare system, specialized immunology and neurology services, and growing clinical requirements for plasma-derived therapies. Intravenous immunoglobulin is utilized for patients with selected immunodeficiency, autoimmune, hematological, and neurological conditions where antibody replacement or immunomodulation is required. Hospitals and specialized healthcare centers play an important role in treatment administration and patient monitoring. Increasing awareness and improved diagnosis of immune-related disorders are supporting appropriate therapy utilization. Healthcare providers are also emphasizing efficient management of immunoglobulin supplies because of the specialized plasma-based manufacturing process. Continued development of specialty care supports long-term growth of Canada's intravenous immunoglobulin market.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific is the fastest-growing region in the intravenous immunoglobulin market and is expected to expand at a CAGR of 8.63% during the forecast period. The region accounted for 20.15% of the global market in 2025, representing a market value of USD 2.98 billion. Growth is supported by improving healthcare infrastructure, increasing diagnosis of immune-related disorders, expanding access to specialty treatments, and rising healthcare expenditure. Development of hospitals and specialized treatment centers is increasing availability of immunoglobulin therapy across major markets. Growing awareness of primary immunodeficiencies and neurological conditions is further supporting clinical demand. Expansion of plasma collection and fractionation capabilities also creates opportunities, supporting strong development of the intravenous immunoglobulin market across Asia Pacific.
Japan is an important contributor to the intravenous immunoglobulin market through its sophisticated healthcare system, advanced clinical capabilities, and established treatment infrastructure for immune and neurological disorders. Intravenous immunoglobulin is used across specialized medical settings for selected conditions requiring antibody replacement or immune modulation. The country's aging population and strong emphasis on management of complex chronic diseases contribute to demand for advanced specialty therapies. Hospitals and specialist physicians benefit from sophisticated diagnostic capabilities that facilitate identification and management of immune-mediated conditions. Continued clinical research, improvements in treatment protocols, and availability of specialized healthcare services strengthen Japan's contribution to the Asia Pacific intravenous immunoglobulin market.
China plays a significant role in the intravenous immunoglobulin market due to its large patient population, expanding healthcare infrastructure, growing plasma-derived products industry, and improving access to specialized treatments. Hospitals use intravenous immunoglobulin across various immune, neurological, and hematological applications based on clinical requirements. Increasing diagnosis of immune-related diseases and expansion of tertiary healthcare facilities are supporting treatment demand. Development of domestic plasma collection and fractionation capabilities is also important for improving availability of immunoglobulin products. Continued healthcare modernization, expansion of specialty medical services, and strengthening of domestic plasma-derived therapy manufacturing reinforce China's importance within the Asia Pacific intravenous immunoglobulin market.
Europe accounted for 27.35% of the global intravenous immunoglobulin market in 2025, reaching a market value of USD 4.05 billion. The region is anticipated to grow at a CAGR of 6.94% during the forecast period. Market development is supported by established healthcare systems, strong awareness of immunodeficiency disorders, specialized neurological care, and widespread availability of plasma-derived therapies. Intravenous immunoglobulin is used across hospitals and specialist treatment centers for multiple approved clinical applications requiring antibody replacement or immunomodulatory effects. Established plasma collection and fractionation capabilities contribute to regional product availability. Growing attention to early diagnosis and effective management of immune-mediated conditions further supports expansion of the intravenous immunoglobulin market across Europe.
Germany is an important contributor to the intravenous immunoglobulin market in Europe due to its advanced healthcare infrastructure, strong pharmaceutical industry, established plasma collection capabilities, and specialized clinical services. Hospitals and specialty centers utilize immunoglobulin therapies across immunology, neurology, hematology, and other treatment areas. Advanced diagnostic capabilities support identification of patients with primary immunodeficiencies and immune-mediated diseases that may require immunoglobulin therapy. Germany's strong life sciences ecosystem also supports plasma processing, pharmaceutical manufacturing, clinical research, and development of specialty biological therapies. Continued investment in healthcare services and management of complex immune disorders strengthens Germany's position within the European intravenous immunoglobulin market.
The United Kingdom contributes to the intravenous immunoglobulin market through its established healthcare system, specialist immunology and neurology services, clinical research capabilities, and structured use of plasma-derived therapies. Intravenous immunoglobulin is administered for selected immune deficiencies and autoimmune, neurological, and hematological conditions according to clinical requirements. Specialist healthcare professionals play an important role in patient assessment, treatment selection, administration, and monitoring. Growing understanding of rare immune disorders and improvements in diagnostic capabilities are supporting appropriate identification of patients who may benefit from treatment. Continued development of specialist medical services and evidence-based therapeutic practices supports the United Kingdom's contribution to the European intravenous immunoglobulin market.
Latin America represented 5.45% of the global intravenous immunoglobulin market in 2025, with a market value of USD 0.81 billion. The region is expected to register a CAGR of 7.56% during the forecast period. Growth is supported by improving healthcare infrastructure, increasing access to specialty medicines, growing awareness of immune-related diseases, and expansion of diagnostic capabilities. Hospitals and specialized treatment centers are increasing access to immunoglobulin therapies for patients requiring antibody replacement and immunomodulatory treatment. Improvements in healthcare coverage and development of specialty care services are further supporting demand. Increasing availability of advanced biological therapies and continued healthcare modernization support expansion of the intravenous immunoglobulin market across Latin America.
Brazil is an important contributor to the intravenous immunoglobulin market in Latin America due to its large healthcare system, substantial patient population, growing specialty care infrastructure, and increasing demand for plasma-derived therapies. Hospitals and specialized centers use intravenous immunoglobulin for selected immunological, neurological, and hematological disorders. Increasing physician awareness and improvements in diagnosis of primary immunodeficiencies and immune-mediated conditions are supporting appropriate treatment adoption. Expansion of specialized healthcare facilities is also improving access to complex biological therapies. Development of plasma-related healthcare capabilities and continued investment in specialty medicine reinforce Brazil's importance within the regional intravenous immunoglobulin market.
The Middle East and Africa accounted for 3.8% of the global intravenous immunoglobulin market in 2025, representing a market value of USD 0.56 billion. The region is projected to expand at a CAGR of 6.88% during the forecast period. Market development is supported by improving healthcare infrastructure, expansion of specialty hospitals, growing awareness of immunodeficiency disorders, and increasing availability of advanced biological therapies. Development of diagnostic services is helping healthcare professionals identify patients requiring specialized immune therapies. Investment in modern hospitals and specialty treatment capabilities is also improving access to intravenous immunoglobulin across major healthcare markets. These factors support long-term development of the intravenous immunoglobulin market across the region.
The UAE contributes to the intravenous immunoglobulin market within the Middle East and Africa through its modern healthcare infrastructure, specialized hospitals, advanced diagnostic capabilities, and increasing availability of complex biological therapies. Specialist centers provide treatment for immune, neurological, and hematological conditions that may require immunoglobulin therapy based on individual clinical needs. Development of sophisticated healthcare facilities and recruitment of specialized medical professionals are improving diagnosis and management of complex immune-mediated disorders. The country's strong pharmaceutical distribution infrastructure also supports access to specialized plasma-derived products. Continued investment in advanced healthcare services and specialty medicine strengthens the UAE's role in the regional intravenous immunoglobulin market.
The intravenous immunoglobulin market is moderately concentrated, with major companies such as CSL Behring, Grifols, Takeda Pharmaceutical, Octapharma, Kedrion Biopharma, Biotest, LFB Biotechnologies, ADMA Biologics, and Prothya Biosolutions competing through plasma collection networks, manufacturing capacity, product portfolios, and regulatory approvals. Competition is increasingly driven by reliable plasma supply, expansion of fractionation capacity, new therapeutic indications, and improved immunoglobulin formulations. Vertically integrated companies benefit from controlling plasma collection through manufacturing and distribution, while leading participants continue investing in capacity expansion and clinical development to meet growing demand for plasma-derived therapies.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
Cancer Biomarker Market Size, Share, Growth, Forecast, 2034
Biomarkers Market Size, Share, Growth, Analysis, Report, 2034
Hematology Diagnostics Market Size, Share, Growth, Analysis, 2034
Protein Purification and Isolation Market Size, Share, 2034
Cell and Gene Therapy Market Size, Share, Growth, 2034
Oncology Biosimilar Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com